Alcon to acquire Lensar in deal worth up to $430 million
Key takeaways:
- Alcon will buy Lensar’s outstanding shares for $14 per share.
- The deal is expected to close in the second half of 2025.
Alcon will expand its femtosecond laser-assisted cataract surgery offerings with a deal to acquire Lensar, according to a press release.
Alcon will buy all of Lensar’s outstanding shares for $14 per share in cash. It will also offer an additional $2.75 per share with the condition that more than 614,000 cumulative procedures are performed with Lensar’s products between Jan. 1, 2026, and Dec. 31, 2027, giving the acquisition a potential value of about $430 million, according to the release.
The deal includes the Ally robotic cataract laser treatment system, Streamline software technology and the Lensar legacy laser system, according to the release.
Alcon expects the transaction to close later this year.
“We are excited for the opportunity to bring Lensar’s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,” Alcon CEO David Endicott said in the release. “By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.”
Perspective
Back to Top
Lensar, as a company with a single technology to focus on, has brought more innovation to femtosecond laser cataract surgery than any other company in the years since these devices first came to market. Lensar has an incredibly loyal and growing base of users.
Pairing those assets with Alcon’s global reach means more patients worldwide can benefit from even better femtosecond technology.
Read more about